Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/predicting-cost-effectiveness-of-generic-vs-brand-dabigatran-using-ShNLCyBqBO
References (50)
-
H. Halkin, Jonathan Shapiro, D. Kurnik, R. Loebstein, V. Shalev, E. Kokia (2003)
Increased warfarin doses and decreased international normalized ratio response after nationwide generic switchingClinical Pharmacology & Therapeutics, 74
-
Anuj Shah, A. Shewale, C. Hayes, B. Martin (2016)
Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation PatientsStroke, 47
-
Medicaid Web site. -
S. Wann, A. Curtis, C. January, K. Ellenbogen, J. Lowe, N. Estes, R. Page, M. Ezekowitz, D. Slotwiner, W. Jackman, W. Stevenson, C. Tracy, V. Fuster, L. Rydén, D. Cannom, J. Heuzey, H. Crijns, S. Olsson, E. Prystowsky, J. Halperin, J. Tamargo, G. Kay, L. Wann, Jeffrey Anderson, N. Albert, J. Hochman, C. Buller, F. Kushner, M. Creager, E. Ohman, S. Ettinger, R. Guyton, L. Tarkington, C. Yancy (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Circulation, 123 1
-
J. Douxfils, F. Buckinx, F. Mullier, Valentine Minet, V. Rabenda, J. Reginster, P. Hainaut, O. Bruyère, J. Dogné (2014)
Dabigatran Etexilate and Risk of Myocardial Infarction, Other Cardiovascular Events, Major Bleeding, and All‐Cause Mortality: A Systematic Review and Meta‐analysis of Randomized Controlled TrialsJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 3
-
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, B. Popescu, U. Schotten, B. putte, P. Vardas (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.European heart journal, 37 38
-
Lung (1993)
Atrial fibrillation: Current understandings and research imperativesJournal of the American College of Cardiology, 22
-
P. Kirchhof, S. Benussi, D. Kotecha, A. Ahlsson, D. Atar, B. Casadei, M. Castellà, H. Diener, H. Heidbuchel, J. Hendriks, G. Hindricks, A. Manolis, J. Oldgren, B. Popescu, U. Schotten, B. putte, P. Vardas, S. Agewall, J. Camm, G. Esquivias, W. Budts, S. Carerj, F. Casselman, A. Coca, R. Caterina, S. Deftereos, D. Dobrev, J. Ferro, G. Filippatos, D. Fitzsimons, B. Gorenek, M. Guenoun, S. Hohnloser, P. Kolh, G. Lip, A. Manolis, J. McMurray, P. Ponikowski, R. Rosenhek, F. Ruschitzka, I. Savelieva, Sanjay Sharma, P. Suwalski, J. Tamargo, C. Taylor, I. Gelder, A. Voors, S. Windecker, J. Zamorano, K. Zeppenfeld (2016)
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 18 11
-
(2003)
retrospective analysis -
Pharmacy drug pricing. National Average Drug Acquisition Costs. Medicaid Web site -
F. Dentali, M. Donadini, N. Clark, M. Crowther, D. Garcia, E. Hylek, D. Witt, W. Ageno (2011)
Brand Name versus Generic Warfarin: A Systematic Review of the LiteraturePharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 31
-
C. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. Casey, M. Drazner, G. Fonarow, S. Geraci, T. Horwich, J. Januzzi, Maryl Johnson, E. Kasper, W. Levy, F. Masoudi, P. Mcbride, J. McMurray, J. Mitchell, Pamela Peterson, B. Riegel, F. Sam, L. Stevenson, W. Tang, E. Tsai, B. Wilkoff (2013)
2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.Circulation, 128 16
-
P. Meredith (2003)
Bioequivalence and other unresolved issues in generic drug substitution.Clinical therapeutics, 25 11
-
S. Ghate, J. Biskupiak, X. Ye, M. Hagan, W. Kwong, E. Fox, D. Brixner (2011)
Hemorrhagic and Thrombotic Events Associated with Generic Substitution of Warfarin in Patients with Atrial Fibrillation: A Retrospective AnalysisAnnals of Pharmacotherapy, 45
-
S. Schmidt, Sarah Kim, Valvanera Vozmediano, Rodrigo Cristofoletti, A. Winterstein, Joshua Brown (2019)
Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology—What's Next?—Joining Mechanistic and Epidemiological ApproachesCPT: Pharmacometrics & Systems Pharmacology, 8
-
C. January, L. Wann, H. Calkins, Lin Chen, Joaquin Cigarroa, Joseph Cleveland, P. Ellinor, M. Ezekowitz, Michael Field, K. Furie, P. Heidenreich, Katherine Murray, Julie Shea, C. Tracy, C. Yancy (2019)
2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart rhythm
-
(1994)
Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials.Archives of internal medicine, 154 13
-
Sheila Richton-Hewett, E. Foster, C. Apstein (1988)
Medical and economic consequences of a blinded oral anticoagulant brand change at a municipal hospital.Archives of internal medicine, 148 4
-
C. January, L. Wann, J. Alpert, H. Calkins, J. Cigarroa, J. Cleveland, J. Conti, P. Ellinor, M. Ezekowitz, M. Field, K. Murray, R. Sacco, W. Stevenson, P. Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation, 130 23
-
R. Pisters, D. Lane, R. Nieuwlaat, C. Vos, H. Crijns, G. Lip (2010)
A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey.Chest, 138 5
-
M. Fang, A. Go, Yuchiao Chang, E. Hylek, Lori Henault, Nancy Jensvold, D. Singer (2007)
Death and disability from warfarin-associated intracranial and extracranial hemorrhages.The American journal of medicine, 120 8
-
Chintan Dave, A. Hartzema, A. Kesselheim (2017)
Prices of Generic Drugs Associated with Numbers of Manufacturers.The New England journal of medicine, 377 26
-
S. Connolly, M. Ezekowitz, S. Yusuf, J. Eikelboom, J. Oldgren, A. Parekh, J. Pogue, P. Reilly, E. Themeles, Jeanne Varrone, Susan Wang, M. Alings, D. Xavier, Jun Zhu, R. Diaz, B. Lewis, H. Darius, H. Diener, C. Joyner, L. Wallentin (2009)
Dabigatran versus warfarin in patients with atrial fibrillation.The New England journal of medicine, 361 12
-
Medicaid drug rebate program -
S. Dunne, C. Dunne (2015)
What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugsBMC Medicine, 13
-
Statistical approaches to establishing bioequivalence: guidance for industry -
R. Hart, L. Pearce, M. Aguilar (2007)
Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 146
-
C. Dansirikul, T. Lehr, Karl‐Heinz Liesenfeld, S. Haertter, A. Staab (2012)
A combined pharmacometric analysis of dabigatran etexilate in healthy volunteers and patients with atrial fibrillation or undergoing orthopaedic surgeryThrombosis and Haemostasis, 107
-
Drug approval package: Pradaxa (dabigatran etexilate mesylate) NDA 022512 -
P. Misir (2019)
A Systematic Review of the LiteratureHIV/AIDS and Adolescents
-
M. Hellfritzsch, J. Rathe, T. Stage, S. Thirstrup, E. Grove, P. Damkier, A. Pottegård (2016)
Generic switching of warfarin and risk of excessive anticoagulation: a Danish nationwide cohort studyPharmacoepidemiology and Drug Safety, 25
-
M. Coppens, J. Eikelboom, R. Hart, S. Yusuf, G. Lip, P. Dorian, O. Shestakovska, S. Connolly (2013)
The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy.European heart journal, 34 3
-
C. January, L. Wann, J. Alpert, H. Calkins, J. Cigarroa, J. Cleveland, J. Conti, P. Ellinor, M. Ezekowitz, M. Field, K. Murray, R. Sacco, W. Stevenson, P. Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.Journal of the American College of Cardiology, 64 21
-
J. Olesen, C. Torp-Pedersen, M. Hansen, G. Lip (2012)
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0–1: A nationwide cohort studyThrombosis and Haemostasis, 107
-
B. Davit, P. Nwakama, Gary Buehler, D. Conner, S. Haidar, Dewrat Patel, Yongsheng Yang, Lawrence Yu, J. Woodcock (2009)
Comparing Generic and Innovator Drugs: A Review of 12 Years of Bioequivalence Data from the United States Food and Drug AdministrationAnnals of Pharmacotherapy, 43
-
Table 2.5.4. Price indexes for personal consumption expenditures by function -
S. Adie, J. Naylor, I. Harris (2010)
A Systematic Review and Meta-Analysis of Randomized Controlled Trials -
(2018)
A Model and Systems Based Approach to Safety and Efficacy Questions Related to Generic Substitution -
Stephen Lahaye, S. Gibbens, D. Ball, A. Day, J. Olesen, A. Skanes (2012)
A clinical decision aid for the selection of antithrombotic therapy for the prevention of stroke due to atrial fibrillationEuropean Heart Journal, 33
-
R. Page, J. Joglar, M. Caldwell, H. Calkins, J. Conti, B. Deal, N. Estes, M. Field, Z. Goldberger, S. Hammill, J. Indik, B. Lindsay, B. Olshansky, A. Russo, W. Shen, C. Tracy, S. Al‐Khatib (2016)
2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.Heart rhythm, 13 4
-
J. Pereira, A. Holbrook, L. Dolovich, C. Goldsmith, L. Thabane, J. Douketis, M. Crowther, S. Bates, Jeffrey Ginsberg (2005)
Are Brand-Name and Generic Warfarin Interchangeable? Multiple N-of-1 Randomized, Crossover TrialsAnnals of Pharmacotherapy, 39
-
J. Olesen, C. Torp-Pedersen, M. Hansen, G. Lip (2018)
The value of the CHA 2 DS 2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS 2 score 0 – 1 : A nationwide cohort study -
C. January, L. Wann, Joseph Alpert, H. Calkins, Joaquin Cigarroa, Joseph Cleveland, Jamie Conti, P. Ellinor, M. Ezekowitz, Michael Field, Katherine Murray, Ralph Sacco, William Stevenson, Patrick Tchou, C. Tracy, C. Yancy (2014)
2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.Circulation, 130 23
-
E. Pritchett (1992)
Management of atrial fibrillation.The New England journal of medicine, 326 19
-
Te-Yu Lin, Fu-Chi Yang, Cheng-Li Lin, C. Kao, Hsin-Yi Lo, Tse-Yen Yang (2016)
Herpes zoster infection increases the risk of peripheral arterial diseaseMedicine, 95
-
L. Wann, A. Curtis, C. January, K. Ellenbogen, J. Lowe, N. Estes, R. Page, M. Ezekowitz, D. Slotwiner, W. Jackman, W. Stevenson, C. Tracy, V. Fuster, L. Rydén, D. Cannom, J. Heuzey, H. Crijns, S. Olsson, E. Prystowsky, J. Halperin, J. Tamargo, G. Kay, A. Jacobs, Jeffrey Anderson, N. Albert, J. Hochman, C. Buller, F. Kushner, M. Creager, E. Ohman, S. Ettinger, R. Guyton, L. Tarkington, C. Yancy (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (Updating the 2006 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Journal of the American College of Cardiology, 57 2
-
R. Nation, L. Sansom (1994)
Bioequivalence requirements for generic products.Pharmacology & therapeutics, 62 1-2
-
O. Jolobe, G. Lip, M. Metcalfe, A. Rae (1993)
Management of paroxysmal atrial fibrillation.The Quarterly journal of medicine, 86 8
-
J. Weitz, Karen Earl, K. Leblanc, W. Semchuk, F. Jamali (2018)
Establishing Therapeutic Equivalence of Complex Pharmaceuticals: The Case of Dabigatran.The Canadian journal of cardiology, 34 9
-
Samuel Wann, A. Curtis, K. Ellenbogen, N. Estes, M. Ezekowitz, W. Jackman, C. January, J. Lowe, R. Page, D. Slotwiner, W. Stevenson, C. Tracy, V. Fuster, L. Rydén, D. Cannom, H. Crijns, J. Halperin, G. Kay, J. Heuzey, S. Olsson, E. Prystowsky, J. Tamargo, L. Wann, A. Jacobs, Jeffrey Anderson, N. Albert, M. Creager, S. Ettinger, R. Guyton, J. Hochman, F. Kushner, E. Ohman, C. Yancy (2011)
2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran). A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.Heart rhythm, 8 3
- Publisher
- Wiley
- Copyright
- © 2020 ASCPT.
- ISSN
- 1752-8054
- eISSN
- 1752-8062
- DOI
- 10.1111/cts.12719
- Publisher site
- See Article on Publisher Site
Abstract
Journal
Clinical and Translational Science – Wiley
Published: Mar 1, 2020